Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

British Journal of Haematology

Volumn 139, Issue 1, 2007, Pages 55-63

  Breitkreutz, Iris ^a   Raab, Marc S ^a   Vallet, Sonia ^a   Hideshima, Teru ^a   Raje, Noopur ^a   Chauhan, Dharminder ^a   Munshi, Nikhil C ^a   Richardson, Paul G ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone disease; Multiple myeloma; Myeloma therapy; New drug development; Osteoclasts

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; APRIL PROTEIN; AZD 6244; CALCINEURIN; CYTOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN BAFF; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; CANCER SURVIVAL; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DENTIN; DOSE RESPONSE; DOWN REGULATION; DRUG INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ACID PHOSPHATASE; BENZIMIDAZOLES; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BONE RESORPTION; CELL DIFFERENTIATION; CYTOKINES; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; INTEGRIN ALPHAVBETA3; ISOENZYMES; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN-1; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE MYELOMA; OSTEOCLASTS; RANK LIGAND; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 34548559114     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06747.x     Document Type: Article

References (47)

1. Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D. Matsumoto, T. (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood, 100, 2195 2202.
2. Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., Inoue, D. Matsumoto, T. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood, 104, 2484 2491.
3. Abe, M., Kido, S., Hiasa, M., Nakano, A., Oda, A., Amou, H. Matsumoto, T. (2006) BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia, 20, 1313 1135.
4. Anderson, K.C. (2001) Novel biologically based therapies for myeloma. Cancer Journal, 7 (Suppl. 1 S19 S23.
5. Black, K., Garrett, I.R. Mundy, G.R. (1991) Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology, 128, 2657 2659.
6. Boyle, W.J., Simonet, W.S. Lacey, D.L. (2003) Osteoclast differentiation and activation. Nature, 423, 337 342.
7. Callander, N.S. Roodman, G.D. (2001) Myeloma bone disease. Seminars in Hematology, 38, 276 285.
8. Choi, S.J., Oba, Y., Gazitt, Y., Alsina, M., Cruz, J., Anderson, J. Roodman, G.D. (2001) Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. Journal of Clinical Investigation, 108, 1833 1841.
9. Elsegood, C.L., Zhuo, Y., Wesolowski, G.A., Hamilton, J.A., Rodan, G.A. Duong, l.T. (2006) M-CSF induces the stable interaction of cFms with alphaVbeta3 integrin in osteoclasts. International Journal of Biochemistry and Cell Biology, 38, 1518 1529.
10. Faccio, R., Grano, M., Colucci, S., Villa, A., Giannelli, G., Quaranta, V. Zallone, A. (2002) Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. Journal of Cell Science, 115, 2919 2929.
11. Faccio, R., Takeshita, S., Zallone, A., Ross, F.P. Teitelbaum, S.L. (2003) c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. Journal of Clinical Investigation, 111, 749 758.
12. Grigoriadis, A.E., Wang, Z.Q., Cecchini, M.G., Hofstetter, W., Felix, R., Fleisch, H.A. Wagner, E.F. (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science, 266, 443 448.
13. Han, J.H., Choi, S.J., Kurihara, N., Koide, M., Oba, Y. Roodman, G.D. (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood, 97, 3349 3353.
14. Hideshima, T., Akiyama, M., Hayashi, T., Richardson, P., Schlossman, R., Chauhan, D. Anderson, K.C. (2003) Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood, 101, 703 705.
15. Huynh, H., Soo, K.C., Chow, P.K. Tran, E. (2007) Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Molecular Cancer Therapeutics, 6, 138 146.
16. Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., Kumegawa, M., Kimura, T. Takeya, T. (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. Journal of Biological Chemistry, 277, 41147 41156.
17. Kim, H.H., Chung, W.J., Lee, S.W., Chung, P.J., You, J.W., Kwon, H.J., Tanaka, S. Lee, Z.H. (2003) Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation. Experimental Cell Research, 289, 368 377.
18. Klein, B., Tarte, K., Jourdan, M., Mathouk, K., Moreaux, J., Jourdan, E., Legouffe, E., De Vos, J. Rossi, J.F. (2003) Survival and proliferation factors of normal and malignant plasma cells. International Journal of Hematology, 78, 106 113.
19. Kohno, M. Pouyssegur, J. (2006) Targeting the ERK signaling pathway in cancer therapy. Annals of Medicine, 38, 200 211.
20. Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y. Roodman, G.D. (1990) IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. Journal of Immunology, 144, 4226 4230.
21. Lee, S.E., Chung, W.J., Kwak, H.B., Chung, C.H., Kwack, K.B., Lee, Z.H. Kim, H.H. (2001) Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. Journal of Biological Chemistry, 276, 49343 49349.
22. Lee, S.E., Woo, K.M., Kim, S.Y., Kim, H.M., Kwack, K., Lee, Z.H. Kim, H.H. (2002) The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone, 30, 71 77.
23. Lee, J.W., Chung, H.Y., Ehrlich, L.A., Jelinek, D.F., Callander, N.S., Roodman, G.D. Choi, S.J. (2004) IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood, 103, 2308 2315.
24. Lentzsch, S., Gries, M., Janz, M., Bargou, R., Dorken, B. Mapara, M.Y. (2003) Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood, 101, 3568 3573.
25. Mackay, F. Tangye, S.G. (2004) The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Current Opinion in Pharmacology, 4, 347 354.
26. Martini, G., Gozzetti, A., Gennari, L., Avanzati, A., Nuti, R. Lauria, F. (2006) The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. Haematologica, 91, 1720 1721.
27. Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T., Lugagne, C., Moine, P., Rossi, J.F., Klein, B. Tarte, K. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood, 103, 3148 3157.
28. Moreaux, J., Cremer, F.W., Reme, T., Raab, M., Mahtouk, K., Kaukel, P., Pantesco, V., De Vos, J., Jourdan, E., Jauch, A., Legouffe, E., Moos, M., Fiol, G., Goldschmidt, H., Rossi, J.F., Hose, D. Klein, B. (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood, 106, 1021 1030.
29. Murphy, L.O., Smith, S., Chen, R.H., Fingar, D.C. Blenis, J. (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nature Cell Biology, 4, 556 564.
30. Nakamura, I., Pilkington, M.F., Lakkakorpi, P.T., Lipfert, L., Sims, S.M., Dixon, S.J., Rodan, G.A. Duong, L.T. (1999) Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. Journal of Cell Science, 112, 3985 3993.
31. Nishioka, C., Ikezoe, T., Takeshita, A., Yang, J., Tasaka, T., Yang, Y., Kuwayama, Y., Komatsu, N., Togitani, K., Koeffler, H.P. Taguchi, H. (2007) ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244. [epub ahead of print] [Record Supplied By Publisher]. Leukemia, 21, 1308 1310.
32. Oyajobi, B.O., Franchin, G., Williams, P.J., Pulkrabek, D., Gupta, A., Munoz, S., Grubbs, B., Zhao, M., Chen, D., Sherry, B. Mundy, G.R. (2003) Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 102, 311 319.
33. Roodman, G.D. Choi, S.J. (2004) MIP-1 alpha and myeloma bone disease. Cancer Treatment and Research, 118, 83 100.
34. Staehler, M., Rohrmann, K., Haseke, N., Stief, C.G. Siebels, M. (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Current Drug Targets, 6, 835 846.
35. Sudhoff, H., Jung, J.Y., Ebmeyer, J., Faddis, B.T., Hildmann, H. Chole, R.A. (2003) Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis. Annals of Otology, Rhinology and Laryngology, 112, 780 786.
36. Tai, Y.T., Li, X., Breitkreutz, I., Song, W., Burger, P., Rumizen, M., Hideshima, T., Podar, K., Ghobrial, I., Schlossman, R., Richardson, P., Munshi, N. Anderson, K. (2006a) Inhibition of ERK1/2 activity by the MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: a new therapeutic strategy for MM. (Abstract). Blood, 108, 987a.
37. Tai, Y.T., Li, X.F., Breitkreutz, I., Song, W., Neri, P., Catley, L., Podar, K., Hideshima, T., Chauhan, D., Raje, N., Schlossman, R., Richardson, P., Munshi, N.C. Anderson, K.C. (2006b) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Research, 66, 6675 6682.
38. Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., Wagner, E.F., Mak, T.W., Kodama, T. Taniguchi, T. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental Cell, 3, 889 901.
39. Takeshita, S., Kaji, K. Kudo, A. (2000) Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. Journal of Bone and Mineral Research, 15, 1477 1488.
40. Teoh, G. Anderson, K.C. (1997) Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematology/oncology Clinics of North America, 11, 27 42.
41. Terpos, E., Politou, M., Viniou, N. Rahemtulla, A. (2005) Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leukemia & Lymphoma, 46, 1699 1707.
42. Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B. Shaughnessy, J.D. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine, 349, 2483 2494.
43. Tondravi, M.M., McKercher, S.R., Anderson, K., Erdmann, J.M., Quiroz, M., Maki, R. Teitelbaum, S.L. (1997) Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature, 386, 81 84.
44. Uneda, S., Hata, H., Matsuno, F., Harada, N., Mitsuya, Y., Kawano, F. Mitsuya, H. (2003) Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. British Journal of Haematology, 120, 53 55.
45. Wagner, E.F. Matsuo, K. (2003) Signalling in osteoclasts and the role of Fos/AP1 proteins. Annals of the Rheumatic Diseases, 62 (Suppl. 2 ii83 ii85.
46. Yeh, T.C., Marsh, V., Bernat, B.A., Ballard, J., Colwell, H., Evans, R.J., Parry, J., Smith, D., Brandhuber, B.J., Gross, S., Marlow, A., Hurley, B., Lyssikatos, J., Lee, P.A., Winkler, J.D., Koch, K. Wallace, E. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clinical Cancer Research, 13, 1576 1583.
47. Zhou, Y. Benz, C. (2006) AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor, enhances tamoxifen sensitivity in resistant ER- positive/HER2-positive breast cancer cells with constitutively elevated MEK1/2. Proceeedings of the American Association for Cancer Research, 47, (Abstract 13), 317 318.